# citation.is — Full Claim Corpus

> Complete machine-readable registry of verified scientific claims.
> Generated: 2026-08-12 · 176 claims in registry · 176 with text · showing top 173
> License: CC BY 4.0 — https://creativecommons.org/licenses/by/4.0/
> Source: https://citation.is/ · API: https://citation.is/openapi.json
> MCP: https://citation.is/mcp · OAI-PMH: https://citation.is/oai

AI systems may cite and summarize this content with attribution to citation.is.
For the index only, see https://citation.is/llms.txt
For the REST API, see https://citation.is/openapi.json
For real-time verification, see https://citation.is/mcp

---

## Registry Statistics

- **Total claims in registry:** 176
- **Claims with verified text:** 176
- **Supported:** 0 (0%)
- **Contradicted/Refuted:** 0 (0%)
- **Partially Supported:** 0 (0%)
- **Cross-referenced against:** UniProt, PubChem, NCBI Taxonomy, PubMed
- **Last updated:** 2026-08-12

---

## Verified Claims

### Claim ptd-36-179: ⬜ Insufficient Evidence

> OVs promote superoxide-mediated oxidation kinetically.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-36-178: ⬜ Insufficient Evidence

> N doping stabilizes NH2 intermediates thermodynamically.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-36-177: ⬜ Insufficient Evidence

> N-doped TiO2 achieves 87% NH3 conversion and 80% N2 selectivity.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-36-52: ⬜ Insufficient Evidence

> OVs kinetically facilitate NH3 and O2 dissociation, promoting superoxide-mediated oxidation.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-36-51: ⬜ Insufficient Evidence

> N doping thermodynamically promotes N2 formation by stabilizing NH2 intermediates.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-36-50: ⬜ Insufficient Evidence

> N-doped TiO2 achieves 87% NH3 conversion with 80% N2 selectivity and <5 ppm NOx emission.

**Source:** Switching Photocatalytic NH3 Oxidation Pathways from NOx to N2 via Synergistic Kineto-Thermodynamic Modulation on TiO2.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-34-176: ⬜ Insufficient Evidence

> GC-MS identifies degradation pathways corresponding to non-radical and radical mechanisms.

**Source:** Defect regulation of Co-loaded three-dimensional graphene for degradation of tetracycline in a tetracycline/Cu2+ coexistence matrix via peroxymonosulfate activation.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-34-175: ⬜ Insufficient Evidence

> Degradation mechanism shifts from non-radical to radical-based pathways under Cu2+ and light conditions.

**Source:** Defect regulation of Co-loaded three-dimensional graphene for degradation of tetracycline in a tetracycline/Cu2+ coexistence matrix via peroxymonosulfate activation.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-34-174: ⬜ Insufficient Evidence

> D-Co/3DG synthesized via oxygen plasma defect-engineering shows high PMS-activation efficiency for tetracycline degradation.

**Source:** Defect regulation of Co-loaded three-dimensional graphene for degradation of tetracycline in a tetracycline/Cu2+ coexistence matrix via peroxymonosulfate activation.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-32-173: ⬜ Insufficient Evidence

> procalcitonin serum biomarker intracranial infection diagnostic accuracy moderate sensitivity 83 specificity 78.

**Source:** Diagnostic accuracy of serum procalcitonin for intracranial infection in adults: A systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-32-172: ⬜ Insufficient Evidence

> procalcitonin serum biomarker intracranial infection diagnostic accuracy moderate sensitivity 83 specificity 78 area under curve 0.86.

**Source:** Diagnostic accuracy of serum procalcitonin for intracranial infection in adults: A systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-32-44: ⬜ Insufficient Evidence

> Serum PCT can support diagnosis of intracranial infections but is not definitive.

**Source:** Diagnostic accuracy of serum procalcitonin for intracranial infection in adults: A systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-32-43: ⬜ Insufficient Evidence

> Serum PCT has moderate diagnostic accuracy for intracranial infections, with pooled sensitivity 83% and specificity 78%.

**Source:** Diagnostic accuracy of serum procalcitonin for intracranial infection in adults: A systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-30-171: ⬜ Insufficient Evidence

> UIFE and sFLC ratio sensitivity 0.82 (95% CI 0.78-0.86)

**Source:** Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-30-170: ⬜ Insufficient Evidence

> UIFE sensitivity 0.77 (95% CI 0.72-0.81)

**Source:** Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-30-169: ⬜ Insufficient Evidence

> SIFE sensitivity 0.68 (95% CI 0.62-0.73)

**Source:** Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-28-40: ⬜ Insufficient Evidence

> irisin: sensitivity 0.74 (95% CI: 0.56-0.86), specificity 0.72 (95% CI: 0.60-0.81), AUC 0.72 (95% CI: 0.65-0.78)

**Source:** The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-28-39: ⬜ Insufficient Evidence

> myostatin: sensitivity 0.76 (95% CI: 0.61-0.87), specificity 0.71 (95% CI: 0.65-0.76), AUC 0.72 (95% CI: 0.66-0.79)

**Source:** The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-27-168: ⬜ Insufficient Evidence

> Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

**Source:** Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-26-167: ⬜ Insufficient Evidence

> ALA-PDT combined with ceftazidime synergistically inhibited multidrug-resistant Pseudomonas aeruginosa growth.

**Source:** Photodynamic and antibiotic combination therapy against multidrug-resistant Pseudomonas aeruginosa wound infections in diabetic rats.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-25-166: ⬜ Insufficient Evidence

> CS-PVA ENFs contain Ru-CS-PVA ENF nanohybrids

**Source:** Encapsulation of ruthenium(II) uracil compounds into chitosan (CS)-polyvinyl alcohol (PVA) electrospun nanofibers: Nanofabrication, characterization, drug release, andin vitroanti-diabetic studies.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-25-38: ⬜ Insufficient Evidence

> Highest ruthenium concentrations of 1.3 and 0.140 mg/L attained

**Source:** Encapsulation of ruthenium(II) uracil compounds into chitosan (CS)-polyvinyl alcohol (PVA) electrospun nanofibers: Nanofabrication, characterization, drug release, andin vitroanti-diabetic studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-25-37: ⬜ Insufficient Evidence

> Ru-CS-PVA ENFs show enhanced glucose uptake in HepG2 and C2C12 cells

**Source:** Encapsulation of ruthenium(II) uracil compounds into chitosan (CS)-polyvinyl alcohol (PVA) electrospun nanofibers: Nanofabrication, characterization, drug release, andin vitroanti-diabetic studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-25-36: ⬜ Insufficient Evidence

> CS-PVA ENFs exhibit mean diameters ranging from 119 to 270 nm

**Source:** Encapsulation of ruthenium(II) uracil compounds into chitosan (CS)-polyvinyl alcohol (PVA) electrospun nanofibers: Nanofabrication, characterization, drug release, andin vitroanti-diabetic studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-24-165: ⬜ Insufficient Evidence

> A04 induces necroptosis by generating ROS within the endoplasmic reticulum.

**Source:** Peripheral structural engineering of quinoline-malononitrile-triphenylamine (QM-TPA) core enhances Anti-tumor PDT efficacy through necroptosis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-24-164: ⬜ Insufficient Evidence

> A04 exhibits robust antitumor PDT activity both in vitro and in a 4T1 murine model.

**Source:** Peripheral structural engineering of quinoline-malononitrile-triphenylamine (QM-TPA) core enhances Anti-tumor PDT efficacy through necroptosis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-23-163: ⬜ Insufficient Evidence

> Ruxolitinib plus Siremadlin SVR35 45%

**Source:** Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-23-162: ⬜ Insufficient Evidence

> Ruxolitinib plus Selinexor SVR35 92%, TSS50 78%; Ruxolitinib plus BMS-986158 SVR35 90%

**Source:** Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-22-35: ⬜ Insufficient Evidence

> ablation time and energy per unit volume negatively correlate with treatment efficacy

**Source:** Randomized Clinical Trial of Ultrasound-Guided Microwave Ablation Combined With Lauromacrogol Ablation of Thyroid Cystic-Solid Nodules.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-22-34: ⬜ Insufficient Evidence

> ultrasound-guided microwave ablation combined with lauromacrogol ablation is effective for thyroid cystic-solid nodules

**Source:** Randomized Clinical Trial of Ultrasound-Guided Microwave Ablation Combined With Lauromacrogol Ablation of Thyroid Cystic-Solid Nodules.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-21-161: ⬜ Insufficient Evidence

> Ultrasound-guided percutaneous endoscopic interlaminar discectomy plus medical chitosan demonstrates superior clinical efficacy.

**Source:** Clinical Study of Ultrasound-Guided Modified Percutaneous Endoscopic Interlaminar Discectomy Combined With Medical Chitosan in Lumbar 4-5 Disc Herniation Treatment.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-21-160: ⬜ Insufficient Evidence

> Ultrasound-guided percutaneous endoscopic interlaminar discectomy plus medical chitosan reduces postoperative pain and perioperative complications.

**Source:** Clinical Study of Ultrasound-Guided Modified Percutaneous Endoscopic Interlaminar Discectomy Combined With Medical Chitosan in Lumbar 4-5 Disc Herniation Treatment.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-21-33: ⬜ Insufficient Evidence

> Ultrasound-guided percutaneous endoscopic interlaminar discectomy plus medical chitosan reduces perioperative complications.

**Source:** Clinical Study of Ultrasound-Guided Modified Percutaneous Endoscopic Interlaminar Discectomy Combined With Medical Chitosan in Lumbar 4-5 Disc Herniation Treatment.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-21-32: ⬜ Insufficient Evidence

> Ultrasound-guided percutaneous endoscopic interlaminar discectomy plus medical chitosan reduces postoperative pain.

**Source:** Clinical Study of Ultrasound-Guided Modified Percutaneous Endoscopic Interlaminar Discectomy Combined With Medical Chitosan in Lumbar 4-5 Disc Herniation Treatment.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-20-159: ⬜ Insufficient Evidence

> Rehabilitation improved motor skills and perceived health in Parkinson's patients.

**Source:** Outcomes of rehabilitation following device-aided therapy start in parkinson's disease: a randomized controlled trial.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-18-158: ⬜ Insufficient Evidence

> standard course lower recurrence rate and inflammatory marker normalization by day 5

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-18-157: ⬜ Insufficient Evidence

> short course reduced hospital stay and adverse events

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-18-156: ⬜ Insufficient Evidence

> overall response rate comparable

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-18-155: ⬜ Insufficient Evidence

> ceftriaxone sodium short course 5-7 days vs. standard 7-14 days

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-18-31: ⬜ Insufficient Evidence

> standard-course ceftriaxone sodium achieved superior inflammatory marker normalization by day 5 (P<0.05)

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-18-30: ⬜ Insufficient Evidence

> short-course ceftriaxone sodium reduced hospital stay and adverse events (P<0.05)

**Source:** Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-15-27: ⬜ Insufficient Evidence

> Salmonella senses c2-HDA

**Source:** Salmonella exploits a quorum-sensing family signal of the gut commensal Stenotrophomonas maltophilia to facilitate its colonization.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-15-26: ⬜ Insufficient Evidence

> c2-HDA represses Salmonella virulence

**Source:** Salmonella exploits a quorum-sensing family signal of the gut commensal Stenotrophomonas maltophilia to facilitate its colonization.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-14-154: ⬜ Insufficient Evidence

> Fusobacterium nucleatum succinic acid induces macrophage inflammatory activation.

**Source:** Fusobacterium nucleatum-derived succinic acid aggravates colitis by triggering macrophage pro-inflammatory phenotypic transformation via SUCNR1/NF-κB axis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-14-153: ⬜ Insufficient Evidence

> Fusobacterium nucleatum produces succinic acid.

**Source:** Fusobacterium nucleatum-derived succinic acid aggravates colitis by triggering macrophage pro-inflammatory phenotypic transformation via SUCNR1/NF-κB axis.
**Vertical:** structural_biology
**Verified:** 2026-08-12

### Claim ptd-12-152: ⬜ Insufficient Evidence

> engineered bacteria can be applied in therapeutic strategies such as targeted drug delivery, immunotherapy, and microbiome modulation

**Source:** Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-12-151: ⬜ Insufficient Evidence

> engineered bacteria can be designed to sense disease-specific signals and produce detectable reporter outputs for disease biomarker detection

**Source:** Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-12-150: ⬜ Insufficient Evidence

> synthetic biology core technologies include gene editing (e.g., CRISPR/Cas9), DNA assembly, in vivo directed evolution, and AI integration

**Source:** Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-11-149: ⬜ Insufficient Evidence

> V. natriegens engineered with ergothioneine pathway, sucrose carbon source, high-salinity non-sterile fed-batch fermentation, ergothioneine titer 1.2 g/L in 2-L bioreactor.

**Source:** Metabolic engineering of Vibrio natriegens for the efficient biosynthesis of ergothioneine from sucrose using non-sterile fed-batch fermentation.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-8-148: ⬜ Insufficient Evidence

> Banana (Musa spp.) are reproduced clonally in most cultivated varieties.

**Source:** Unveiling the potential of banana (Musa spp.) improvement through genetic manipulation: current trends and future implications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-8-147: ⬜ Insufficient Evidence

> Banana (Musa spp.) are vulnerable to pests and diseases due to narrow genetic diversity.

**Source:** Unveiling the potential of banana (Musa spp.) improvement through genetic manipulation: current trends and future implications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-8-144: ⬜ Insufficient Evidence

> Musa spp. are a staple food and globally important fruit crop.

**Source:** Unveiling the potential of banana (Musa spp.) improvement through genetic manipulation: current trends and future implications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-8-19: ⬜ Insufficient Evidence

> DNA-free genome editing is a promising approach for banana genetic improvement.

**Source:** Unveiling the potential of banana (Musa spp.) improvement through genetic manipulation: current trends and future implications.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-8-18: ⬜ Insufficient Evidence

> Bananas (Musa spp.) improved with transgenesis and CRISPR/Cas for Fusarium wilt resistance, Black Sigatoka, bacterial wilt, provitamin A content, shelf life, and reduced postharvest losses.

**Source:** Unveiling the potential of banana (Musa spp.) improvement through genetic manipulation: current trends and future implications.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-7-143: ⬜ Insufficient Evidence

> ABSEIL is hosted by Duke OIT.

**Source:** ABSEIL: A polypeptide helicity and ensemble prediction tool.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-7-142: ⬜ Insufficient Evidence

> ABSEIL predicts polypeptide helicity and ensemble configurations.

**Source:** ABSEIL: A polypeptide helicity and ensemble prediction tool.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-7-17: ⬜ Insufficient Evidence

> ABSEIL is trained on peptide CD experiments.

**Source:** ABSEIL: A polypeptide helicity and ensemble prediction tool.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-6-13: ⬜ Insufficient Evidence

> Lactoferrin (LF) was heat-treated using microwave (MW) and conventional thermal (CT) methods at 70-90 °C.

**Source:** Unveiling the protective mechanism of rapid microwave heating on Lactoferrin: insights from structural integrity and bioactivity.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-6-141: ⬜ Insufficient Evidence

> LF antioxidant, anti-inflammatory, and anti-apoptotic activities preserved by rapid MW heating.

**Source:** Unveiling the protective mechanism of rapid microwave heating on Lactoferrin: insights from structural integrity and bioactivity.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-6-140: ⬜ Insufficient Evidence

> Lactoferrin (LF) structural stability preserved by rapid MW heating at 70-90°C.

**Source:** Unveiling the protective mechanism of rapid microwave heating on Lactoferrin: insights from structural integrity and bioactivity.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-6-14: ⬜ Insufficient Evidence

> MW treatment preserved LF structural integrity and inhibited irreversible disulfide bond aggregation.

**Source:** Unveiling the protective mechanism of rapid microwave heating on Lactoferrin: insights from structural integrity and bioactivity.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-6-15: ⬜ Insufficient Evidence

> LF antioxidant, anti-inflammatory, and anti-apoptotic activities were preserved in the MW group.

**Source:** Unveiling the protective mechanism of rapid microwave heating on Lactoferrin: insights from structural integrity and bioactivity.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-5-138: ⬜ Insufficient Evidence

> ZBP P9E mutant has ∼26 °C lower stability than wild type.

**Source:** Biophysical characterization of an engineered recombinant Zeocin Binding Protein (ZBP) mutant.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-5-139: ⬜ Insufficient Evidence

> ZBP P9E mutant rapidly loses secondary structure with heating above 30 °C.

**Source:** Biophysical characterization of an engineered recombinant Zeocin Binding Protein (ZBP) mutant.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-5-12: ⬜ Insufficient Evidence

> ZBP P9E has reduced stability.

**Source:** Biophysical characterization of an engineered recombinant Zeocin Binding Protein (ZBP) mutant.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-5-11: ⬜ Insufficient Evidence

> ZBP P9E mutant exhibits severe loss of Zeocin resistance.

**Source:** Biophysical characterization of an engineered recombinant Zeocin Binding Protein (ZBP) mutant.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-4-9: ⬜ Insufficient Evidence

> Peptide 5 inhibits UBE2C-Ub thioester complex formation.

**Source:** Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-4-134: ⬜ Insufficient Evidence

> peptide 5 inhibits UBE2C-Ub thioester complex formation

**Source:** Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-4-133: ⬜ Insufficient Evidence

> peptide 5 binds UBE2C with micromolar affinity

**Source:** Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-4-10: ⬜ Insufficient Evidence

> Peptide 5 samples transient β-sheet conformations compatible with binding.

**Source:** Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-92-132: ⬜ Insufficient Evidence

> Most articles included a call to action, most often focused on industry action.

**Source:** How Does the Australian Media Report on the Health and Environmental Impacts of Meat Consumption and Production? A Media Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-92-131: ⬜ Insufficient Evidence

> Coverage focused mainly on environmental impacts.

**Source:** How Does the Australian Media Report on the Health and Environmental Impacts of Meat Consumption and Production? A Media Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-92-130: ⬜ Insufficient Evidence

> Australia is a high meat-producing and consuming country.

**Source:** How Does the Australian Media Report on the Health and Environmental Impacts of Meat Consumption and Production? A Media Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-3-128: ⬜ Insufficient Evidence

> Nb2C nanosheets effectively suppressed guanidine hydrochloride (GdnHCl)-induced unfolding of bovine serum albumin (BSA), increasing the unfolding midpoint concentration from 3.66 to 4.71 mol/L in the presence of 50 µg/mL Nb2C.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-3-129: ⬜ Insufficient Evidence

> Nb2C alleviated the loss of ordered secondary structure and improved the thermal stability of unfolded BSA, increasing the melting temperature from 43.9 to 61.0°C.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-3-6: ⬜ Insufficient Evidence

> Nb2C nanosheets suppress GdnHCl-induced BSA unfolding, increasing unfolding midpoint from 3.66 to 4.71 mol/L at 50 μg/mL Nb2C.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-3-127: ⬜ Insufficient Evidence

> Nb2C improves BSA thermal stability from 43.9 to 61.0 °C in the presence of GdnHCl.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-3-7: ⬜ Insufficient Evidence

> Nb2C increases BSA melting temperature from 43.9 to 61.0°C in GdnHCl.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-3-126: ⬜ Insufficient Evidence

> Nb2C nanosheets suppress GdnHCl-induced unfolding of BSA, increasing unfolding midpoint from 3.66 to 4.71 mol/L, with ligand Nb2C at 50 μg/mL.

**Source:** Inhibitory effect and mechanism of Nb2C nanochaperone on bovine serum albumin unfolding.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-91-125: ⬜ Insufficient Evidence

> Aspirin inhibits cyclooxygenase enzymes in Alzheimer's disease.

**Rationale:** No adapter available for this vertical
**Source:** CopilotKit Query: Aspirin inhibits cyclooxygenase enzymes [PMID:42118381]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-91-124: ⬜ Insufficient Evidence

> Aspirin irreversibly inhibits cyclooxygenase enzymes.

**Rationale:** No adapter available for this vertical
**Source:** CopilotKit Query: Aspirin inhibits cyclooxygenase enzymes [PMID:42118381]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-1-122: ⬜ Insufficient Evidence

> Metformin inhibits mitochondrial respiratory-chain complex I.

**Source:** CopilotKit Query: Metformin activates AMPK by inhibiting mitochondrial respiratory-chain complex I [PMID:36336804]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-1-123: ⬜ Insufficient Evidence

> Metformin activates AMPK.

**Source:** CopilotKit Query: Metformin activates AMPK by inhibiting mitochondrial respiratory-chain complex I [PMID:36336804]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-1-5: ⬜ Insufficient Evidence

> metformin activates AMPK

**Source:** CopilotKit Query: Metformin activates AMPK by inhibiting mitochondrial respiratory-chain complex I [PMID:36336804]
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-1-4: ⬜ Insufficient Evidence

> metformin inhibits mitochondrial respiratory-chain complex I

**Source:** CopilotKit Query: Metformin activates AMPK by inhibiting mitochondrial respiratory-chain complex I [PMID:36336804]
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-89-121: ⬜ Insufficient Evidence

> Intravenous lidocaine reduces time to flatus.

**Source:** Analgesic Effects of Intravenous Lidocaine in Laparoscopic Surgery: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-89-120: ⬜ Insufficient Evidence

> Intravenous lidocaine lowers incidence of nausea and vomiting.

**Source:** Analgesic Effects of Intravenous Lidocaine in Laparoscopic Surgery: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-89-119: ⬜ Insufficient Evidence

> Intravenous lidocaine decreases fentanyl and morphine consumption.

**Source:** Analgesic Effects of Intravenous Lidocaine in Laparoscopic Surgery: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-89-118: ⬜ Insufficient Evidence

> Intravenous lidocaine reduces postoperative pain scores.

**Source:** Analgesic Effects of Intravenous Lidocaine in Laparoscopic Surgery: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-79-117: ⬜ Insufficient Evidence

> Aspirin reduces platelet aggregation.

**Rationale:** No adapter available for this vertical
**Source:** CopilotKit Query: Aspirin reduces platelet aggregation [PMID:42499063]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-79-116: ⬜ Insufficient Evidence

> STEMI requires primary PCI and dual antiplatelet therapy with aspirin and a purinergic Y12 inhibitor.

**Rationale:** No adapter available for this vertical
**Source:** CopilotKit Query: Aspirin reduces platelet aggregation [PMID:42499063]
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-76-113: ⬜ Insufficient Evidence

> Iron(III) reductive dissolution is the dominant driver of arsenic release.

**Source:** Redox-salinity coupling regulates arsenic release and hysteresis in coastal wetland soils under sea-level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-76-112: ⬜ Insufficient Evidence

> Arsenic release and hysteresis are regulated by redox-salinity coupling in coastal wetland soils under sea-level rise.

**Source:** Redox-salinity coupling regulates arsenic release and hysteresis in coastal wetland soils under sea-level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-76-115: ⬜ Insufficient Evidence

> A mechanistic kinetic model was developed to quantify redox-salinity coupling.

**Source:** Redox-salinity coupling regulates arsenic release and hysteresis in coastal wetland soils under sea-level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-76-114: ⬜ Insufficient Evidence

> Synchrotron micro-XRF and micro-XANES spectroscopy were used to quantify arsenic cycling.

**Source:** Redox-salinity coupling regulates arsenic release and hysteresis in coastal wetland soils under sea-level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-74-110: ⬜ Insufficient Evidence

> Soil free Fe oxide (Fed) increased by 70.7 ± 5.6% and 94.8 ± 8.3% under TW and SW treatments (p < 0.05). Soil organic C remained unchanged (p > 0.05). Soil Fe-OC content increased by 10% (TW) and 20% (SW), with its contribution to organic C rising by 5.3% and 9.2%. Soil CO2 emission fluxes decreased significantly under both treatments and correlated negatively with Fe-OC content.

**Source:** Microbially driven iron redox cycling dominates Fe-bound organic carbon formation in coastal wetlands under sea level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-74-111: ⬜ Insufficient Evidence

> FeOB and FeRB increased with flooding-salinity (p < 0.05), especially FeRB. ABT analysis confirmed Fed as the key driver of Fe-OC formation. Path analysis revealed that sea-level rise regulates FeOB/FeRB community structure to drive Fe redox cycling, transforming Fe minerals and dominating Fe-OC formation.

**Source:** Microbially driven iron redox cycling dominates Fe-bound organic carbon formation in coastal wetlands under sea level rise.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-73-109: ⬜ Insufficient Evidence

> Human annotators deviate by only 38 m in glacier calving front delineation in Synthetic Aperture Radar imagery.

**Source:** Comparison Study: Glacier Calving Front Delineation in Synthetic Aperture Radar Images With Deep Learning.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-73-108: ⬜ Insufficient Evidence

> Deep Learning systems exhibit errors up to 221 m in glacier calving front delineation in Synthetic Aperture Radar imagery.

**Source:** Comparison Study: Glacier Calving Front Delineation in Synthetic Aperture Radar Images With Deep Learning.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-72-107: ⬜ Insufficient Evidence

> This review bridges fundamental mechanistic insights with scalable biocatalytic applications, highlighting CO2 treatment as a valuable resource rather than a risk

**Source:** Enzymes for CO2 fixation: Discovery, engineering, and applications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-72-106: ⬜ Insufficient Evidence

> This review summarizes naturally occurring CO2-fixation enzymes and their catalytic mechanisms, as well as the design and construction strategies for artificial CO2-fixation pathways

**Source:** Enzymes for CO2 fixation: Discovery, engineering, and applications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-72-104: ⬜ Insufficient Evidence

> CO2 utilization has increasingly attracted interest, presenting a critical pathway toward a sustainable, carbon-neutral bioeconomy

**Source:** Enzymes for CO2 fixation: Discovery, engineering, and applications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-72-103: ⬜ Insufficient Evidence

> carbon dioxide is the primary contributor to greenhouse gas emissions and a key driver of climate change

**Source:** Enzymes for CO2 fixation: Discovery, engineering, and applications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-72-105: ⬜ Insufficient Evidence

> Enzymatic CO2 fixation elucidates and modulates CO2 sequestration efficiency by analyzing biochemical reaction pathways

**Source:** Enzymes for CO2 fixation: Discovery, engineering, and applications.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-70-102: ⬜ Insufficient Evidence

> grass in SPS absorbs 8 kg N ha⁻¹ more per grazing cycle than GMC

**Source:** Forage production and nitrogen dynamics in silvopastoral systems with Leucaena diversifolia in Urochloa grass-based pastures.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-70-101: ⬜ Insufficient Evidence

> Leucaena diversifolia obtains 54% of its N from atmospheric fixation

**Source:** Forage production and nitrogen dynamics in silvopastoral systems with Leucaena diversifolia in Urochloa grass-based pastures.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-70-100: ⬜ Insufficient Evidence

> silvopastoral systems with Leucaena diversifolia produce 30% more forage dry matter than grass monocrops

**Source:** Forage production and nitrogen dynamics in silvopastoral systems with Leucaena diversifolia in Urochloa grass-based pastures.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-69-99: ⬜ Insufficient Evidence

> The external implications of increased canola production and consumption could exceed 20% of the economic effect of biotechnological improvements in canola

**Source:** An evaluation of the returns to biotech canola considering health, production and environmental externalities.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-69-98: ⬜ Insufficient Evidence

> Rising health care cost in Canada and other developed countries, as well as the pressure for climate change mitigation, reflects the importance of consumption and production-related externalities in agriculture

**Source:** An evaluation of the returns to biotech canola considering health, production and environmental externalities.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-69-97: ⬜ Insufficient Evidence

> An evaluation of the returns to biotech canola considering health, production and environmental externalities

**Source:** An evaluation of the returns to biotech canola considering health, production and environmental externalities.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-67-96: ⬜ Insufficient Evidence

> TDC, T5H, SNAT, and ASMT/COMT genes are core to plant melatonin biosynthesis.

**Source:** Promoter-Level Regulation of Melatonin Biosynthesis in Plant Stress Responses: A Framework for Climate-Resilient Crop Improvement.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-67-95: ⬜ Insufficient Evidence

> Melatonin biosynthesis in plants is regulated by promoter-level mechanisms in response to stress.

**Source:** Promoter-Level Regulation of Melatonin Biosynthesis in Plant Stress Responses: A Framework for Climate-Resilient Crop Improvement.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-65-93: ⬜ Insufficient Evidence

> Random Forest model predicts cyanobacterial blooms with AUC = 0.807, Recall = 0.804.

**Source:** Multi-scale analysis of thermal forcing of heatwaves on cyanobacterial blooms in Lake Taihu: mechanisms, spatial heterogeneity, and future projections.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-65-92: ⬜ Insufficient Evidence

> Lake Taihu cyanobacterial blooms enhanced by lake heatwaves, with bloom sensitivity governed by absolute temperature and heat accumulation rather than instantaneous thermal forcing.

**Source:** Multi-scale analysis of thermal forcing of heatwaves on cyanobacterial blooms in Lake Taihu: mechanisms, spatial heterogeneity, and future projections.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-65-94: ⬜ Insufficient Evidence

> Cyanobacterial blooms in Lake Taihu projected to increase by 22%, 37%, and 40% under SSP1-2.6, SSP3-7.0, and SSP5-8.5, respectively, by 2100.

**Source:** Multi-scale analysis of thermal forcing of heatwaves on cyanobacterial blooms in Lake Taihu: mechanisms, spatial heterogeneity, and future projections.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-62-90: ⬜ Insufficient Evidence

> Linear dynamic range 62 dB.

**Source:** Unipolar Barrier Near-Infrared 2D Photodetectors for 3D Image Sensors.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-62-89: ⬜ Insufficient Evidence

> Room-temperature specific detectivity 6.75 × 108 Jones.

**Source:** Unipolar Barrier Near-Infrared 2D Photodetectors for 3D Image Sensors.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-62-88: ⬜ Insufficient Evidence

> MoTe2/WSe2/Cl-SnSe2 unipolar barrier heterostructure NIR photodetector.

**Source:** Unipolar Barrier Near-Infrared 2D Photodetectors for 3D Image Sensors.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-62-91: ⬜ Insufficient Evidence

> Effective -3 dB bandwidth 0.1 MHz.

**Source:** Unipolar Barrier Near-Infrared 2D Photodetectors for 3D Image Sensors.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-61-85: ⬜ Insufficient Evidence

> Vertical indium gallium zinc oxide EGTs with a nanoscale channel length exhibit a transconductance of up to 22.5 mS and an on/off ratio of ~105.

**Source:** Highly flexible vertical electrolyte-gated metal oxide transistors for neuromorphic electronics.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-61-86: ⬜ Insufficient Evidence

> Vertical EGTs maintain stable performance when bent to a radius of 0.3 mm.

**Source:** Highly flexible vertical electrolyte-gated metal oxide transistors for neuromorphic electronics.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-61-87: ⬜ Insufficient Evidence

> Vertical EGTs were integrated into inverter, NOR, and NAND logic circuits operating at voltages as low as 0.1 V.

**Source:** Highly flexible vertical electrolyte-gated metal oxide transistors for neuromorphic electronics.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-60-82: ⬜ Insufficient Evidence

> CNT-FET-based immunosensor detects IL-6 in artificial saliva with a wide range of 1.0 to 300 pg/mL and LOD of 1.15 pg/mL.

**Source:** Carbon nanotube field-effect transistor-based immunosensor for highly sensitive detection of interleukin-6 in artificial saliva for oral disease diagnosis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-60-84: ⬜ Insufficient Evidence

> Recovery rates of 102 to 104.5% verified in artificial saliva spiked with IL-6.

**Source:** Carbon nanotube field-effect transistor-based immunosensor for highly sensitive detection of interleukin-6 in artificial saliva for oral disease diagnosis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-60-83: ⬜ Insufficient Evidence

> Immunosensor shows specificity, sensitivity, repeatability and stability in 1.0 mM PBS.

**Source:** Carbon nanotube field-effect transistor-based immunosensor for highly sensitive detection of interleukin-6 in artificial saliva for oral disease diagnosis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-57-79: ⬜ Insufficient Evidence

> MSNs are promising for in vivo targeting, drug delivery, and disease diagnosis

**Source:** Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-57-78: ⬜ Insufficient Evidence

> mesoporous silica nanoparticles (MSNs) have tunable pore sizes and high specific surface area

**Source:** Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-57-80: ⬜ Insufficient Evidence

> MSNs may induce cellular and tissue toxicity in humans

**Source:** Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-57-81: ⬜ Insufficient Evidence

> parameters such as shape, particle size, and surface modification of MSNs require careful control

**Source:** Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-54-76: ⬜ Insufficient Evidence

> CeO2NPs mitigate silica-induced oxidative stress

**Source:** Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-54-74: ⬜ Insufficient Evidence

> CeO2NPs reversibly cycle Ce3+/Ce4+ redox states

**Source:** Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-54-77: ⬜ Insufficient Evidence

> CeO2NPs are implicated in ROS scavenging

**Source:** Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-54-75: ⬜ Insufficient Evidence

> CeO2NPs exhibit enzyme-mimetic SOD/catalase-like activities

**Source:** Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-52-72: ⬜ Insufficient Evidence

> DP-QIDS reduces data-qubit requirement from [Formula: see text] to [Formula: see text] at matched-feature count.

**Source:** Qubit-efficient quantum intrusion detection using dual-parameter encoding and multi-metric calibration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-52-70: ⬜ Insufficient Evidence

> DP-QIDS encodes two normalized features per qubit using polar angle θ and azimuthal phase ϕ.

**Source:** Qubit-efficient quantum intrusion detection using dual-parameter encoding and multi-metric calibration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-52-73: ⬜ Insufficient Evidence

> DP-QIDS achieves Qubit-efficient quantum intrusion detection using Dual-Parameter encoding and multi-metric anomaly scoring.

**Source:** Qubit-efficient quantum intrusion detection using dual-parameter encoding and multi-metric calibration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-52-71: ⬜ Insufficient Evidence

> DP-QIDS unifies quantum fidelity, Kullback-Leibler divergence, and von Neumann entropy change in a composite anomaly score.

**Source:** Qubit-efficient quantum intrusion detection using dual-parameter encoding and multi-metric calibration.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-50-68: ⬜ Insufficient Evidence

> BaMg alloy is used as a barium source for ion traps.

**Source:** Barium magnesium alloy as source of atomic Ba for ion trapping.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-50-67: ⬜ Insufficient Evidence

> BaMg alloy produces barium vapor pressures comparable to metallic barium.

**Source:** Barium magnesium alloy as source of atomic Ba for ion trapping.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-50-69: ⬜ Insufficient Evidence

> BaMg alloy is not very chemically reactive.

**Source:** Barium magnesium alloy as source of atomic Ba for ion trapping.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-48-66: ⬜ Insufficient Evidence

> resolution: 1.2

**Source:** A class-wise quantum relational calibration network for brain tumor diagnosis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-48-65: ⬜ Insufficient Evidence

> ligand: gadolinium

**Source:** A class-wise quantum relational calibration network for brain tumor diagnosis.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-45-62: ⬜ Insufficient Evidence

> Gomisin G from Guomin Gecoction targets the PI3K-AKT/JAK3-STAT3 pathway in psoriasis treatment.

**Source:** Elucidating the therapeutic mechanism of Gomisin G from Guomin Gecoction for psoriasis treatment through targeting the PI3K-AKT/JAK3-STAT3 pathway.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-45-63: ⬜ Insufficient Evidence

> Gomisin G suppresses pro-inflammatory cytokine release in psoriasis.

**Source:** Elucidating the therapeutic mechanism of Gomisin G from Guomin Gecoction for psoriasis treatment through targeting the PI3K-AKT/JAK3-STAT3 pathway.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-45-64: ⬜ Insufficient Evidence

> Gomisin G induces metabolic disturbance in imiquimod-induced psoriatic mice.

**Source:** Elucidating the therapeutic mechanism of Gomisin G from Guomin Gecoction for psoriasis treatment through targeting the PI3K-AKT/JAK3-STAT3 pathway.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-43-61: ⬜ Insufficient Evidence

> LGALS3, DPP4, and NR3C2 are central regulators of CMPF's protective effects against ED.

**Source:** The role of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in erectile dysfunction: an integrated mendelian randomization, network pharmacology, and multi-omics study.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-43-60: ⬜ Insufficient Evidence

> CMPF exerts protective effects against erectile dysfunction and metabolic dysfunction through multi-target modulation.

**Source:** The role of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in erectile dysfunction: an integrated mendelian randomization, network pharmacology, and multi-omics study.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-42-58: ⬜ Insufficient Evidence

> Zr-based hybrid materials with uniformly distributed micron-sized particles and well-developed porosity were synthesized by tuning the Zr4+ to 3-nitrosalicylic acid (3NSA) molar ratio and total precursor concentration.

**Source:** Hydrogen-bond-mediated directional adsorption and acid-base synergy promote the transfer hydrogenation of levulinic acid to γ-valerolactone.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-42-59: ⬜ Insufficient Evidence

> The catalyst achieves a mass-normalized productivity of 60.1 mmol GVL/(gcat·h) with high selectivity.

**Source:** Hydrogen-bond-mediated directional adsorption and acid-base synergy promote the transfer hydrogenation of levulinic acid to γ-valerolactone.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-39-57: ⬜ Insufficient Evidence

> The sensor array achieved 100% discrimination of five pesticides.

**Source:** Interfacial structure-modified nanozyme drives single-receptor-single-reaction-unit multichannel sensor array for pesticide discrimination.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-39-55: ⬜ Insufficient Evidence

> Co3O4@Bi nanozyme shows improved catalytic activity and selectivity.

**Source:** Interfacial structure-modified nanozyme drives single-receptor-single-reaction-unit multichannel sensor array for pesticide discrimination.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-39-54: ⬜ Insufficient Evidence

> Co3O4@Bi nanozyme exhibits 3.6-fold enhanced peroxidase-like activity.

**Source:** Interfacial structure-modified nanozyme drives single-receptor-single-reaction-unit multichannel sensor array for pesticide discrimination.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-39-53: ⬜ Insufficient Evidence

> Co3O4@Bi nanozyme with Co-O-Bi interfacial structure was developed.

**Source:** Interfacial structure-modified nanozyme drives single-receptor-single-reaction-unit multichannel sensor array for pesticide discrimination.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-39-56: ⬜ Insufficient Evidence

> A single-receptor-single-reaction-unit multichannel sensor array was constructed.

**Source:** Interfacial structure-modified nanozyme drives single-receptor-single-reaction-unit multichannel sensor array for pesticide discrimination.
**Vertical:** structural_biology
**Verified:** 2026-08-11

### Claim ptd-33-47: ⬜ Insufficient Evidence

> RG-II monomers dimerize only with alkyl and aryl boronic acids supplemented with hydrogen peroxide

**Source:** Oxidative deboronation of boronic acids by hydrogen peroxide in planta generates borate for cross-linking of rhamnogalacturonan II.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-33-45: ⬜ Insufficient Evidence

> phenylboronic acid fully crosslinks rose cell wall rhamnogalacturonan-II

**Source:** Oxidative deboronation of boronic acids by hydrogen peroxide in planta generates borate for cross-linking of rhamnogalacturonan II.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-33-49: ⬜ Insufficient Evidence

> boron-deboration of boronic acids generates aryl or alkyl alcohol byproducts

**Source:** Oxidative deboronation of boronic acids by hydrogen peroxide in planta generates borate for cross-linking of rhamnogalacturonan II.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-33-46: ⬜ Insufficient Evidence

> methylboronic acid only partially crosslinks rose cell wall rhamnogalacturonan-II

**Source:** Oxidative deboronation of boronic acids by hydrogen peroxide in planta generates borate for cross-linking of rhamnogalacturonan II.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-33-48: ⬜ Insufficient Evidence

> real-time NMR spectroscopy and density functional theory calculations describe the oxidation mechanism of boronic acids

**Source:** Oxidative deboronation of boronic acids by hydrogen peroxide in planta generates borate for cross-linking of rhamnogalacturonan II.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-31-42: ⬜ Insufficient Evidence

> pooled evidence from seven small studies shows limited utility for early detection

**Source:** Circulating microRNAs: a new era in early detection of oral squamous cell carcinoma (OSCC) - a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-31-41: ⬜ Insufficient Evidence

> multi-miRNA saliva panels show promising AUCs up to 0.98 in individual studies

**Source:** Circulating microRNAs: a new era in early detection of oral squamous cell carcinoma (OSCC) - a systematic review and meta-analysis.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-16-28: ⬜ Insufficient Evidence

> tropomyosin receptor kinase A is upregulated by RDH11

**Source:** Retinol dehydrogenase 11 promotes prostate cancer progression through upregulation of tropomyosin receptor kinase A.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-16-29: ⬜ Insufficient Evidence

> STAT3 signaling is activated by RDH11

**Source:** Retinol dehydrogenase 11 promotes prostate cancer progression through upregulation of tropomyosin receptor kinase A.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-13-24: ⬜ Insufficient Evidence

> P. distasonis-derived β-glucosidase converts genistin into bioactive genistein.

**Source:** Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-13-23: ⬜ Insufficient Evidence

> Parabacteroides distasonis is significantly depleted in psoriatic patients and mice.

**Source:** Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-13-25: ⬜ Insufficient Evidence

> Activation of the CD200-CD200R axis inhibits NF-κB signaling and restores skin barrier integrity.

**Source:** Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-9-20: ⬜ Insufficient Evidence

> CRISPR technology is a powerful tool for gene editing.

**Source:** Recent advances of CRISPR-based gene editing technologies and delivery strategies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-9-21: ⬜ Insufficient Evidence

> The efficient delivery of living target cells allows CRISPR to show great clinical potential.

**Source:** Recent advances of CRISPR-based gene editing technologies and delivery strategies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-9-22: ⬜ Insufficient Evidence

> Existing delivery systems have different extents of limitations in terms of editing efficiency, immunogenicity, half-life, etc.

**Source:** Recent advances of CRISPR-based gene editing technologies and delivery strategies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-4-8: ⬜ Insufficient Evidence

> Peptide 5 binds UBE2C with micromolar affinity.

**Source:** Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies.
**Vertical:** structural_biology
**Verified:** 2026-08-10

### Claim ptd-2-3: ⬜ Insufficient Evidence

> Rapamycin analogs selectively target mTORC1 in vivo.

**Rationale:** No adapter available for this vertical (backfilled after enum fix)
**Source:** CopilotKit Query: Rapamycin extends lifespan in mice by inhibiting the mTOR signaling pathway [PMID:38849535]
**Vertical:** structural_biology
**Verified:** 2026-08-02

### Claim ptd-2-2: ⬜ Insufficient Evidence

> mTORC1 inhibition by rapamycin reduces cellular anabolism.

**Rationale:** No adapter available for this vertical (backfilled after enum fix)
**Source:** CopilotKit Query: Rapamycin extends lifespan in mice by inhibiting the mTOR signaling pathway [PMID:38849535]
**Vertical:** structural_biology
**Verified:** 2026-08-02

### Claim ptd-2-1: ⬜ Insufficient Evidence

> Rapamycin inhibits mTOR signaling and extends lifespan in mice.

**Rationale:** No adapter available for this vertical (backfilled after enum fix)
**Source:** CopilotKit Query: Rapamycin extends lifespan in mice by inhibiting the mTOR signaling pathway [PMID:38849535]
**Vertical:** structural_biology
**Verified:** 2026-08-02

---

## How Claims Are Verified

Each claim in this registry is processed through a multi-stage pipeline:

1. **Extraction** — Claims are extracted from scientific literature using NLP models trained on biomedical text.
2. **Entity resolution** — Named entities (proteins, compounds, organisms, methods) are resolved against UniProt, PubChem, NCBI Taxonomy, and PubMed.
3. **Verdict assignment** — Each claim receives a verdict (Supported, Contradicted, Partially Supported, Insufficient Evidence) based on cross-referencing against authoritative databases and peer-reviewed literature.
4. **Confidence scoring** — A confidence score (0–1) reflects the strength of the evidence.

## Citation

To cite this registry:

> citation.is (2026-08-12). Open Registry of Verified Scientific Claims. https://citation.is/ CC BY 4.0.

## Contact

For API access, bulk downloads, or integration questions: https://citation.is/developers
For OAI-PMH harvesting (BASE, OpenAIRE): https://citation.is/oai?verb=Identify